High-dose omalizumab use in patients with chronic spontaneous urticaria

Mehran Alizadeh Aghdam; Fenne van den Broek; Feiko Rijken; Andre Cornelis Knulst; Heike Röckmann

doi:10.1016/j.jaip.2019.10.018

High-dose omalizumab use in patients with chronic spontaneous urticaria

Mehran Alizadeh Aghdam^*, Fenne van den Broek, Feiko Rijken, Andre Cornelis Knulst, Heike Röckmann

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	1426-1427.e1
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	8
Issue number	4
Early online date	31 Oct 2019
DOIs	https://doi.org/10.1016/j.jaip.2019.10.018
Publication status	Published - 1 Apr 2020

Access to Document

10.1016/j.jaip.2019.10.018

Cite this

@article{6ae4e9161f4e47f1a595622247dd8ecd,

title = "High-dose omalizumab use in patients with chronic spontaneous urticaria",

author = "{Alizadeh Aghdam}, Mehran and {van den Broek}, Fenne and Feiko Rijken and Knulst, {Andre Cornelis} and Heike R{\"o}ckmann",

note = "Funding Information: Conflicts of interest: A. C. Knulst is a member of Advisory Board for Novartis and has received health care innovation grant from Novartis to his institution. H. R{\"o}ckmann is a member of National Advisory Board for Novartis. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = apr,

day = "1",

doi = "10.1016/j.jaip.2019.10.018",

language = "English",

volume = "8",

pages = "1426--1427.e1",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - High-dose omalizumab use in patients with chronic spontaneous urticaria

AU - Alizadeh Aghdam, Mehran

AU - van den Broek, Fenne

AU - Rijken, Feiko

AU - Knulst, Andre Cornelis

AU - Röckmann, Heike

N1 - Funding Information: Conflicts of interest: A. C. Knulst is a member of Advisory Board for Novartis and has received health care innovation grant from Novartis to his institution. H. Röckmann is a member of National Advisory Board for Novartis. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/4/1

Y1 - 2020/4/1

UR - http://www.scopus.com/inward/record.url?scp=85075380606&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2019.10.018

DO - 10.1016/j.jaip.2019.10.018

M3 - Letter

C2 - 31678293

AN - SCOPUS:85075380606

SN - 2213-2198

VL - 8

SP - 1426-1427.e1

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 4

ER -

High-dose omalizumab use in patients with chronic spontaneous urticaria

Access to Document

Other files and links

Cite this